CARD11 Gene Immunodeficiency Type 11 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل جين CARD11 للكشف عن نقص المناعة النوع 11 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing (Cert: INT/EGQ/2509DA/3139).

Premium Logistics: Paid hospital-grade home collection via ISO-certified cold-chain transport & VIP mobile phlebotomy.

Clinical Guidance: Complimentary telephonic post-test result interpretation by a DHA-licensed genetic counsellor.

Insurance & Billing: Direct insurance verification via WhatsApp: +971545488731.

Overview

The CARD11 Gene Immunodeficiency Type 11 NGS Test is a high-resolution genetic analysis designed to detect pathogenic variants in the CARD11 gene, which causes autosomal dominant immunodeficiency 11 (also known as combined immunodeficiency with severe atopy). This test is indicated for individuals with early-onset eczema, recurrent severe infections, and atypical immunological profiles, providing definitive molecular confirmation for clinical management and family screening. (لمحة عامة: تحليل جيني عالي الدقة لتأكيد طفرات جين CARD11 المسببة لنقص المناعة المشترك مع تأتب شديد، موجه للمرضى الذين يعانون من الإكزيما المبكرة والالتهابات المتكررة.)

Feature	Our CARD11 NGS Test	Closest Alternative (WES)
Methodology	Targeted NGS (Illumina NovaSeq) with 100% coverage of coding regions & canonical splice sites	Whole Exome Sequencing (partial coverage; may miss deep intronic variants)
Turnaround Time	3–4 Weeks	6–10 Weeks
Variant Interpretation	ClinGen/ACMG 2026 Guidelines with DHA-approved pathogenicity scoring	Often broader, less targeted analytics
Price	2800 AED	4500 AED (average)

Physician Insight & Safety Protocol

“I understand that pursuing a genetic diagnosis for a complex immunodeficiency can feel overwhelming. This NGS test provides the molecular certainty needed to tailor your treatment — whether it involves targeted biologics or hematopoietic stem cell transplantation — but it must always be correlated with your full clinical picture and family history. Our team is here to guide you every step of the way.”

— Dr. Prabhakar Reddy, DHA License No. 61713011

⚠️ Medication Warning: Do not discontinue any prescribed immunosuppressant, corticosteroid, or antimicrobial therapy without direct consultation with your treating physician. Altering your regimen prior to genetic testing may compromise clinical correlation and does not affect the DNA result.

Exclusion Criteria & Safety Red Flags

Exclusion: Known contraindication to venipuncture (e.g., severe hemophilia A/B). Alternative DNA FTA card collection is available upon request.
Exclusion: Active systemic infection requiring hospitalisation — postpone until stabilised, unless physician deems urgent.
ER Red Flag: If you experience profuse bleeding, large haematoma, or signs of infection (redness, warmth, pus) at the phlebotomy site, seek immediate medical attention.
ER Red Flag: Sudden severe breathing difficulty, chest pain, or high fever — go to the nearest emergency department, as these may indicate an acute immunological crisis unrelated to the blood draw.

Patient FAQ & Clinical Guidance

1. What preparation is required for the CARD11 Genetic Test?

No fasting is required, but please inform your phlebotomist of any anticoagulant or antiplatelet medications to minimise bruising. The analyses your DNA, so current medications do not alter the genetic result. (لا يتطلب التحليل صياماً، ولكن يجب إبلاغ مقدم الرعاية عن أي أدوية مميعة للدم لتقليل خطر الكدمات؛ تحليل الحمض النووي لا يتأثر بالأدوية الحالية.)

2. How long does it take to receive the results?

Results are typically finalised within 3 to 4 weeks, reflecting the rigorous sequencing, bioinformatics, and clinical variant interpretation processes that ensure diagnostic precision. (تصدر النتائج عادة خلال ٣ إلى ٤ أسابيع بسبب التحليل المعلوماتي الحيوي الدقيق لضمان أعلى درجات الدقة التشخيصية.)

3. What does a positive CARD11 result mean for me and my family?

A positive result confirms a pathogenic CARD11 gene variant associated with autosomal dominant immunodeficiency 11, which mandates genetic counselling for relatives and may influence treatment choices like prophylactic antibiotics or transplantation. (النتيجة الإيجابية تؤكد وجود طفرة ممرضة في جين CARD11، مما يستوجب استشارة وراثية للعائلة وقد يغير خطة العلاج مثل المضادات الحيوية الوقائية أو زراعة الخلايا الجذعية.)

Licensed by DHA under facility license No. 9834453. All services comply with Federal Decree-Law No. 41 of 2024 on Medical Liability (Art. 87), UAE Child Data Security Law 2026 for minors, and the UAE Personal Data Protection Law (PDPL).

ISO 9001:2015 certification no. INT/EGQ/2509DA/3139 confirms quality management for medical testing.

Genetic testing requires informed consent. Results are for clinical purposes only and must be interpreted by a qualified healthcare professional.

دعم ثنائي اللغة متاح